Patents Assigned to IMCYSE SA
-
Patent number: 11787849Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.Type: GrantFiled: September 23, 2016Date of Patent: October 17, 2023Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Patent number: 11760782Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.Type: GrantFiled: June 30, 2022Date of Patent: September 19, 2023Assignee: IMCYSE SAInventors: Luc Vander Elst, Vincent Carlier, Jean-Marie Saint-Remy
-
Patent number: 11718650Abstract: The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides.Type: GrantFiled: April 14, 2020Date of Patent: August 8, 2023Assignee: IMCYSE SAInventor: Jean-Marie Saint-Remy
-
Patent number: 11485768Abstract: The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent or separated from said CD1d binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen.Type: GrantFiled: April 19, 2017Date of Patent: November 1, 2022Assignee: IMCYSE SAInventor: Luc Vander Elst
-
Patent number: 11407795Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.Type: GrantFiled: September 14, 2020Date of Patent: August 9, 2022Assignee: IMCYSE SAInventors: Luc Vander Elst, Vincent Carlier, Jean-Marie Saint-Remy
-
Patent number: 11226332Abstract: The present invention relates an in vitro method for detecting class II restricted CD4+ T cells in a sample. Herein a sample is contacted with an isolated complex of an MHC class II molecule and a peptide. This peptide comprises an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. CD4+ T cells are detected by measuring the binding of the complex with cells in the sample, wherein the binding of the complex to a cell is indicative for the presence of CD4+ T cells in the sample. The present invention further relates to an isolated complex of an MHC Class II molecule and a peptide comprising an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif.Type: GrantFiled: July 10, 2019Date of Patent: January 18, 2022Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Vincent Carlier, Luc Vander Elst
-
Publication number: 20200397911Abstract: The invention relates to isolated immunogenic peptides comprising a MHC class II T cell epitope, and immediately adjacent or separated from said epitope a H-X(0,2)-C-X(2)-[CST] or [CST]-X(2)-C-X(0,2)-H redox motif.Type: ApplicationFiled: June 4, 2020Publication date: December 24, 2020Applicant: IMCYSE SAInventors: Jean-Marie SAINT-REMY, Vincent Carlier, Luc Vander Elst, David Burkhart
-
Patent number: 10808016Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.Type: GrantFiled: August 5, 2019Date of Patent: October 20, 2020Assignee: IMCYSE SAInventors: Luc Vander Elst, Vincent Carlier, Jean-Marie Saint-Remy
-
Patent number: 10729791Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.Type: GrantFiled: May 11, 2016Date of Patent: August 4, 2020Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Publication number: 20190106477Abstract: The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent or separated from said CD1d binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen.Type: ApplicationFiled: April 19, 2017Publication date: April 11, 2019Applicant: IMCYSE SAInventor: Luc Vander Elst
-
Publication number: 20180258154Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.Type: ApplicationFiled: September 23, 2016Publication date: September 13, 2018Applicant: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Publication number: 20180228912Abstract: The invention relates to isolated immunogenic peptides comprising a MHC class II T cell epitope, and immediately adjacent or separated from said epitope a H-X(0,2)-C-X(2)-[CST] or [CST]-X(2)-C-X(0,2)-H redox motif.Type: ApplicationFiled: October 16, 2015Publication date: August 16, 2018Applicant: IMCYSE SAInventors: Jean-Marie Saint-Remy, Vincent Carlier, Luc Vander Elst, David Burkhart
-
Patent number: 9394517Abstract: The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them.Type: GrantFiled: December 20, 2013Date of Patent: July 19, 2016Assignee: IMCYSE SAInventor: Jean-Marie Saint-Remy
-
Patent number: 9248171Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an allograft antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of allograft rejection and in the manufacture of medicaments therefore.Type: GrantFiled: February 14, 2008Date of Patent: February 2, 2016Assignee: IMCYSE SAInventor: Jean-Marie Saint-Remy